SCM Lifescience

What do you think about #atopicdermatitis? Do you see it as just a simple skin condition?   Moderate-to-severe atopic dermatitis causes intense itching, which disrupts sleep. Visible symptoms such as rashes and inflammation can interfere with social activities and may lead to mental health issues like anxiety and depression. Atopic dermatitis patients are suffering to the point of experiencing suicidal thoughts. Developing treatments for atopic dermatitis is not about improving quality of life; it’s a matter of life and death. What patients at death’s door need is continuous care and warm perspective. SCM Life Sciences will continue to challenge the development of #AD treatments.   Beyond Relief, Toward Cure

For patients with #Acutepancreatitis (AP) and their families, the journey is nothing short of an arduous expedition. The relentless pain and uncertainty weigh heavily not only on the patients but also on their loved ones. Still, they face each day with resilience and hope as their guiding stars, driven by the dream of a cure. #SCMLifescience likewise stands with them, sharing their passion and strives tirelessly to turn their hopes into reality. Like explorers navigating uncharted territories, we are on a mission to develop a first-in-class treatment for acute pancreatitis. Through groundbreaking research and unwavering dedication, we strive to bring hope and healing to those who need it most. At the end of that journey, pain will turn into healing, and hope will become reality. - Journey for HOPE

What image comes to your mind when you think of #raredisease patients? Are they merely passive individuals enduring suffering while waiting for treatment?   They are vital figures who endure human limitations and drive social change. Their pain and perseverance serve as a catalyst for medical innovation, advancing science and technology and fostering economic and industrial growth. Furthermore, their stories inspire social solidarity and empathy across borders, becoming a source of hope and possibility for patients worldwide. Today, #Graftversushostdisease (GVHD) patients endure severe, body-wide pain while contributing to a better society. SCM Life Sciences will continue to challenge the development of #GVHD treatments.   Beyond Relief, Toward Cure

[Myth vs. Truth] Uncovering the Truth About 'Graft versus Host Disease’ Are you familiar with #Graftversushostdisease (GVHD)? Let’s uncover the truth behind the misconceptions about this condition. Graft-versus-host disease (GVHD) is a severe complication that can occur after hematopoietic stem cell transplantation or organ transplantation. It arises when the donor's immune cells (T cells) recognize the recipient's tissues or organs as foreign and attack them. GVHD is a severe and complex condition where early diagnosis and appropriate treatment significantly influence patient outcomes. Approved treatment options for GVHD currently exist, but there is still room for improvement. Since GVHD is associated with complex immune responses, it remains challenging to treat. As a result, ongoing research focuses on developing new drugs and innovative therapies for patients who do not respond to existing treatments. Recent advancements, such as stem cell therapy, offer new possibilities for managing and treating GVHD, improving the quality of life for patients and paving the way for better care. So, #SCMLifescience is developing a stem cell therapy for chronic Graft-Versus-Host Disease. We are currently in Phase III clinical trials for this indication. In 2019, this program received Orphan Drug Designation (#ODD). The final report for these trials is expected to be available in the second half of 2024. If you want to get more information about us, Follow #SCMLifescience and visit https://lnkd.in/gg6EvBDx

[Myth vs. Truth] Uncovering the Truth About 'Acute Pancreatitis’ #Acutepancreatitis (AP) is well-known in the medical field, but public awareness and understanding of the disease remain relatively low. Let's uncover the truth about this disease. Acutepancreatitis is an acute inflammatory disease of the pancreas caused by various factors that lead to damage to pancreatic acinar cells (exocrine cells of the pancreas). It can result in extensive interstitial edema and hemorrhage in the pancreas, and in some cases, trigger systemic inflammatory responses and multiple organ failure. The treatment of acute pancreatitis goes beyond merely alleviating symptoms; it plays a critical role in preventing complications, improving survival rates, and maintaining the patient's long-term health. But acute pancreatitis is currently treated primarily with symptom-relief-focused approaches, highlighting the urgent need for new therapeutic developments. Advanced technologies, such as stem cell therapy, offer promising potential in regulating inflammation and promoting tissue regeneration. #SCMLifescience is developing a stem cell therapy for moderately severe acute pancreatitis (AP) and has also received Orphan Drug Designation (#ODD) during the development phase. Additionally, we have successfully completed Phase I/IIa trials, with the final results announced in August 2022. Currently, we are preparing for Phase IIb. We always aspire that our efforts bring hope to many patients. If you want to get more information about us, Follow #SCMLifescience and visit https://lnkd.in/gg6EvBDx

#Autoimmunediseases occur when immune cells, which are supposed to protect the body from external invaders such as bacteria, viruses, and fungi, attack the body's own tissues. In other words, immune cells mistakenly recognize the body's normal cells as antigens and attack them. It can affect various parts of the body, such as the thyroid, red blood cells, skin, and joints, and includes diseases like rheumatoid arthritis, lupus, psoriasis, atopic dermatitis, and Crohn's disease. The rapid increase in autoimmune disease incidence is driving the market size to an expected $117.97 billion. Accordingly, domestic pharma and biotech companies are accelerating the development of treatments.   #SCMLifescience has focused on high-purity stem cell therapies since its founding and recently expanded into immuno-oncology, pursuing strategic partnerships and research initiatives. We have also completed Phase 2 trials for the chronic #Graftversushostdisease (GVHD) pipeline and are awaiting the results. #GVHD is a disease that occurs when transplanted immune cells attack the host's tissues following allogeneic hematopoietic stem cell transplantation. It has no fundamental cure and is currently designated as an orphan drug in development. Therefore, we aim to achieve early commercialization through conditional approval in 2025 if efficacy is demonstrated.   More : https://lnkd.in/gbDHNtdp

[Myth vs. Truth] Uncovering the Truth About 'Atopic Dermatitis’ #Atopicdermatitis (AD) is a common and well-known condition, but misconceptions about it still persist. It is a chronic inflammatory skin condition characterized by intense itching and dry skin, with unclear causes, and is classified as an autoimmune disease. Atopic dermatitis significantly impacts the quality of life and requires ongoing care. Global research efforts are advancing rapidly, with innovative therapies, particularly in regenerative medicineand immunotherapy, showing promise. #SCMLifescience's efforts in developing cell therapies for moderately to severely atopic dermatitis are moving forward. This program is transitioning to Phase III in Korea, in collaboration with our partner Handok. The Phase I/II final report was published in May 2023, marking a significant milestone for this indication. Effective treatments and proactive management are crucial to improving the lives of those affected by atopic dermatitis. We always look forward to our efforts will be a great hope for all over the world's patients. If you want to get more information about us, Follow #SCMLifescience and visit https://lnkd.in/gg6EvBDx

The #AdvancedRegenerativeBioAct (ARBA) of Korea is scheduled to be amended on February 21, 2025. This amendment is expected to improve patient access to stem cell therapies, accelerate clinical trials for companies, and advance commercialization by up to four years. The scope of clinical research will expand from patients with severe rare diseases to the general patients. Therapies that previously required approval from the Ministry of Food and Drug Safety (MFDS) can now be introduced during the clinical stage. Additionally, the number of Authorized Human Cell Management Agencies will increase from around 30 to 85.   #SCMLifescience is a leading stem cell therapy development company significantly impacted by the #ARBA. Notably, therapies for #Graftversushostdisease (GVHD) and #Acutepancreatitis (AP), designated as rare drugs in the development stage, are expected to benefit from the ARBA. The ongoing development of a new drug for #GVHD aims to seek conditional approval as soon as its efficacy is confirmed in Phase 2 clinical trials. More : https://lnkd.in/gbDHNtdp

[Myth vs. Truth] Uncovering the Truth About 'Stem cell (Regenerative medicine)’ #Regenerativemedicine is a field of medicine that focuses on replacing or regenerating human cells, tissues, and organs to restore their original functions. Its core technologies include stem cells, biomaterials, tissue engineering, and clinical applications. Especially, #StemCells are transforming the future of medicine with their incredible regenerative capabilities. These unique cells hold the ability to self-renew and differentiate into various mature cell types, offering groundbreaking potential for treating previously untreatable conditions. Harnessing these properties, countries worldwide are advancing stem cell research. #SCMLifescience is leading stem cell therapy to provide high-quality cell therapies for the treatment of intractable diseases. Through our proprietary stem cell technology, the layer separation culture method, we can isolate and culture high-purity stem cell lines. As a result, this year, we were approved as a member company of the North Carolina Regenerative Medicine Biocluster. The institution has secured 200 billion KRW in regenerative medicine commercialization research funding from the U.S. government over the next 10 years. Our company plans to pursue the following business initiatives: - Advancing a global standardization research project for stem cell core technology - Jointly promoting overseas technology transfer of clinical pipelines - Establishing a research and sales network for our cell-based products - Securing an external advisory network for global commercialization efforts Visit www.scmlifescience.com today to learn more about our pioneering work and Join us in shaping the future of regenerative medicine. 

The #StemCellTherapy market is rapidly expanding, around the Asia-Pacific region. Especially, #MesenchymalStemCells (MSCs) are promising players with a significant market share, and their demand is expected to continue growing. Its ability to differentiate into various tissues and regulate immune responses makes it widely used in regenerative medicine, immunology, and degenerative disease research.   #SCMLifescience is a South Korean biotech company specializing in the research and development of stem cell therapies based on #MSCs. We are advancing high-purity, high-efficiency stem cell research with our proprietary technology, #SubfractionationCulturingMethod, collaborating with global bio clusters. We are currently developing treatments for chronic #Graftversushostdisease (GVHD), severe #Acutepancreatitis (AP) and #Atopicdermatitis (AD) with plans to expand the market by broadening indications based on similar mechanisms of action.